A summary of anti-SARS-CoV phytocompounds and their possible therapeutic target and efficiency.

Table 2: A summary of anti-SARS-CoV phytocompounds and their possible therapeutic target and efficiency.

Therapeutic target		Compound	IC₅₀/ EC₅₀	Plant of origin	Ref.
Viral attachment & entry	S-protein	Ginsenoside-Rb1	100 µM	Panax ginseng	[34]
		Glycyrrhizin	> 500 µM	Glycyrrhiza glabra Glycyrrhiza radix	[60,62]
		Cepharanthine	6-9.5 µg/ml	Stephania sp.	[48]
	ACE2	Emodin	200 µM	Rheum rhabarbarum Rheum officinale	[52]
	ACE2	Cepharanthine	0.98 µM	Stephania japonica	[49]
	Unclear	Saikosaponin B2	1.7 µmol/L	Bupleurumchinense	[69]
	Unclear	Lycorine	15.7 µM	Lycoris radiata	[66]
Viral replication	3CL^pro PL^pro	Amentoflavone	8.3 µM	Torreya nucifera	[31]
		Baicalin	11 µM	Scutellaria baicalensis	[40]
		Theaflavin-3,3′-digallate	9.5 µM	Camellia sinensis	[85,86]
		Xanthoangelol E	1.2-11.4 µM	Angelica keiskei	[88]
		Iguesterin	2.6 µM	Triterygium regelii	[89]
		Tingenone	9.9 µM	Triterygium regelii	[89]
		Pristimererin	5.5 µM	Triterygium regelii	[89]
		Celastrol	10.3 µM	Triterygium regelii	[89]
		Quercetin-3-β-galactoside	42.7 µM	Ginkgo biloba	[92]
		Hirsutenone	4.1 µM	Alnus japonica	[93]
		Tanshinones	0.8-30 µM	Salvia miltiorrhiza	[72]
		3-isotheaflavin-3-gallate	7 µM	Camellia sinensis	[85]
		Tannic acid	3 µM	Camellia sinensis	[85]
	Helicase	Myricetin	2.71 µM	Myrica rubra	[94]
	Helicase	Scutellarein	0.86 µM	Scutellaria baicalensis	[94]
	RdRp	Theaflavin	--	Camellia sinensis	[86]
	Unclear	Reserpine	3.4 µM	Rauwolfia sp.	[34]
		Aescin	6.0 µM	Aesculus hippocastanum	[34]
		Tetrandrine	295.6 nM	Stephania tetrandra	[44]